NCT07210606View on ClinicalTrials.gov

Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

June 30, 2030

Study Completion Date

December 31, 2030

Conditions
Sleep Disordered BreathingAble Bodied
Interventions
DRUG

Trazodone + PAP therapy

The central apnea index and the apneic threshold will be compared under two conditions: trazodone or placebo. In addition, participants will get PAP therapy during both the conditions.

DRUG

Oxygen + PAP therapy

The central apnea index and the apneic threshold will be compared under two conditions: oxygen or room air. In addition, participants will get PAP therapy during both the conditions.

Trial Locations (1)

48201-1916

John D. Dingell VA Medical Center, Detroit, MI, Detroit

All Listed Sponsors
lead

VA Office of Research and Development

FED